Shots:
The US FDA has granted 2 FTDs to TT125-802 for NSCLC: one for EGFR exon 19 deletion or exon 21 L858R mutation pts progressing after EGFR inhibitors, & another for KRAS G12C-mutated pts progressing after KRAS G12C inhibitors
TT125-802 is being assessed in P-I trial to evaluate its safety, tolerability, PK, & efficacy in…
